Emily Dworkin

Rotations

Leukemia

PharmD: University of Iowa

PGY1: University of Wisconsin Health
PGY2 Oncology/Hematology: University of Wisconsin Health

Acute leukemias, treatment of leukemia in the adolescent and young adult population, quality improvement and pharmacy practice advancement

Schmiegelow K, Rank CU, Stock W, Dworkin E, van der Sluis I. SOHO State of the art updates and next questions: management of asparaginase toxicity in adolescents and young adults with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(11):725-733.
Patel AA, Heng J, Dworkin E, Monick S, Derman B, et al. Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults. eJHaem. Published online June 2021.
Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152-159.
Dworkin E, Hager D. Taking the fear out of feedback: models for success. J Pharm Soc Wis.2016;19(2):22-25.

Optimal intensive induction for older adults with newly diagnosed acute myeloid leukemia. Presented at the Hematology/Oncology Pharmacy Association Annual Conference. Boston, MA. April 2022
Checkpoint inhibitors in hematologic malignancies. Recorded Lecture for The Hematology/Oncology Pharmacy Association 2021 BCOP Oncology Pharmacy Updates
Advances in targeted therapy for AML: Practical management of BCL-2 inhibitors. Abbvie Sponsored Symposium. Presented at The Hematology/Oncology Pharmacy Association Annual Conference. [Virtual] April 2021

Off label prescribing of novel agents in acute myeloid leukemia, with Jordan Baur, PharmD
The impact of a pharmacist driven protocol for management of 6MP and oral MTX during AML maintenance therapy with Kaitlin Kelly, PharmD, BCOP